The interplay between cell-free DNA, hepcidin, and interleukin-6 in chronic kidney disease induced inflammation and progression to a hemodialysis dependent state.
Reham Hammad, Mona A Eldosoky, Lamiaa Ismaiel, Fatma M Kotb, Omaima I Abo-Elkheir, Hend G Kotb, Wafaa A Emam, Amena R Mohammed, Amany M Tawfik, Mona A Raafat, Doaa L Ali, Sarah F Fahmy, Rasha Elgamal, Fatma El-Zahraa Abd El Hakam, Sonia Distante
{"title":"The interplay between cell-free DNA, hepcidin, and interleukin-6 in chronic kidney disease induced inflammation and progression to a hemodialysis dependent state.","authors":"Reham Hammad, Mona A Eldosoky, Lamiaa Ismaiel, Fatma M Kotb, Omaima I Abo-Elkheir, Hend G Kotb, Wafaa A Emam, Amena R Mohammed, Amany M Tawfik, Mona A Raafat, Doaa L Ali, Sarah F Fahmy, Rasha Elgamal, Fatma El-Zahraa Abd El Hakam, Sonia Distante","doi":"10.55133/eji.320201","DOIUrl":null,"url":null,"abstract":"<p><p>Inflammation drives chronic kidney disease (CKD) progression to end-stage renal disease (ESRD). Cell-free DNA (cfDNA) release is linked to systemic inflammation. Pro-inflammatory interleukin-6 (IL-6) is believed to induce hepcidin, the master regulator of iron metabolism. This study attempts to assess the link between cfDNA, IL-6, and hepcidin in CKD induced inflammation and evaluate their usefulness as indicators for progression. This study included 90 participants, divided into three equal groups. Group 1 comprised non-dialysis dependent CKD (ND-CKD) patients (stages IV and V); Group 2 comprised hemodialysis dependent ESRD (HD-ESRD) patients; and Group 3 comprised study normal controls. cfDNA concentration was determined using the real-time quantitative polymerase chain reaction (RT-qPCR). Serum hepcidin and IL-6 were assessed using enzyme-linked immunosorbent assay (ELISA) kits. The HD-ESRD group showed significant up-regulation of cfDNA, IL-6, and hepcidin compared to the ND-CKD group (p =0.008, p < 0.001, and p < 0.001, respectively) and to the control group (p =0.007, p < 0.001, and p < 0.001, respectively). The ND-CKD group showed no significant up-regulation in cfDNA compared to the control group. cfDNA was positively correlated with IL-6, hepcidin, and carotid intima-media thickness (CIMT). IL-6 had the highest discriminative power to detect CKD progression [area under the curve (AUC) of 0.84, 83% sensitivity (SN) and 73% specificity (SP)], followed by hepcidin [AUC 0.77, SN = 80%, and SP = 63%] and cfDNA [AUC 0.67, SN = 70%, and SP = 50%]. Logistic regression analysis revealed that up-regulated IL-6 and hepcidin were independent predictors of HD-ESRD progression, (odds ratio = 1.005 and 1.006, respectively). In conclusion, cfDNA was associated with IL-6 and hepcidin in CKD. Up-regulated IL-6 and hepcidin can serve as predictors of HD-ESRD progression. cfDNA was associated with CIMT in renal patients. IL-6 and hepcidin up-regulations may act as predictors of HD-ESRD progression.</p>","PeriodicalId":39724,"journal":{"name":"The Egyptian journal of immunology / Egyptian Association of Immunologists","volume":"32 2","pages":"1-16"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Egyptian journal of immunology / Egyptian Association of Immunologists","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55133/eji.320201","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Inflammation drives chronic kidney disease (CKD) progression to end-stage renal disease (ESRD). Cell-free DNA (cfDNA) release is linked to systemic inflammation. Pro-inflammatory interleukin-6 (IL-6) is believed to induce hepcidin, the master regulator of iron metabolism. This study attempts to assess the link between cfDNA, IL-6, and hepcidin in CKD induced inflammation and evaluate their usefulness as indicators for progression. This study included 90 participants, divided into three equal groups. Group 1 comprised non-dialysis dependent CKD (ND-CKD) patients (stages IV and V); Group 2 comprised hemodialysis dependent ESRD (HD-ESRD) patients; and Group 3 comprised study normal controls. cfDNA concentration was determined using the real-time quantitative polymerase chain reaction (RT-qPCR). Serum hepcidin and IL-6 were assessed using enzyme-linked immunosorbent assay (ELISA) kits. The HD-ESRD group showed significant up-regulation of cfDNA, IL-6, and hepcidin compared to the ND-CKD group (p =0.008, p < 0.001, and p < 0.001, respectively) and to the control group (p =0.007, p < 0.001, and p < 0.001, respectively). The ND-CKD group showed no significant up-regulation in cfDNA compared to the control group. cfDNA was positively correlated with IL-6, hepcidin, and carotid intima-media thickness (CIMT). IL-6 had the highest discriminative power to detect CKD progression [area under the curve (AUC) of 0.84, 83% sensitivity (SN) and 73% specificity (SP)], followed by hepcidin [AUC 0.77, SN = 80%, and SP = 63%] and cfDNA [AUC 0.67, SN = 70%, and SP = 50%]. Logistic regression analysis revealed that up-regulated IL-6 and hepcidin were independent predictors of HD-ESRD progression, (odds ratio = 1.005 and 1.006, respectively). In conclusion, cfDNA was associated with IL-6 and hepcidin in CKD. Up-regulated IL-6 and hepcidin can serve as predictors of HD-ESRD progression. cfDNA was associated with CIMT in renal patients. IL-6 and hepcidin up-regulations may act as predictors of HD-ESRD progression.